<?xml version="1.0" encoding="UTF-8"?>
<p>The multi‐stakeholder approach used to develop an investment case for the cost‐effectiveness and affordability of hepatitis control and elimination for South Africa provides a template for other countries.
 <xref rid="liv14222-bib-0044" ref-type="ref">44</xref> Implementation of the investment case‐informed Viral Hepatitis Action Plan is expected to commence on 1st April 2019, with five priority interventions during the first year: (a) hepatitis B birth dose vaccination; (b) healthcare worker hepatitis screening, vaccination and training in viral hepatitis (c) increasing awareness, diagnosis and management of Hepatitis B virus (Tenofovir is on the Essential Medicine list); (d) registration of DAAs and price negotiations; (e) a comprehensive package of viral hepatitis services for key populations – men who have sex with men and people who use/inject drugs.
</p>
